IBD ratings--
MANNKIND CORP RANK WITHIN THE MEDICAL-BIOMED/BIOTECH GROUP (324 STOCKS)
- Composite Rating 57 Rank within Group: 39th
88%- EPS Rating 33 Rank within Group: 102nd
68%- Relative Strength Rating 98 Rank within Group: 16th
95%- SMR Rating(N/A) Rank within Group: N/A
N/A- Acc/Dist. Rating B- Rank within Group: 103rd
68%
Let's see what happens, be a good test of IBD...
Johnathan Clements has rejoined the WSJ, writing a Sunday column. Used to read him all the time, as IMO, he is one of the best personal finance writers ever.
He blends the time-tested methods of wealth-building with the everyday task of living.
Highly recommended.
http://www.jonathanclements.com/